Jefferies has maintained a Hold rating on Entero Healthcare with a target price of ₹1,350, compared to the current market price of ₹1,238. The brokerage noted that the company’s 1QFY26 EBITDA and PAT came in below estimates, primarily due to higher employee costs.
Acquisitions continue to be a key growth driver for Entero, with four of its six recent acquisitions already closed. For FY26, management has maintained guidance of 30% sales growth and EBITDA margins above 4%. However, the company is expected to be more selective in future acquisitions, which Jefferies believes could slow down merger and acquisition-related upside.
Consequently, the brokerage has cut its FY26–FY28 EPS estimates by 2–10% to reflect a more moderate growth trajectory.
Disclaimer: The above views are those of Jefferies. This update is for news reporting purposes only and does not constitute investment advice.
